Canadian taTME expert collaboration (CaTaCO) position statement.


Journal

Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653

Informations de publication

Date de publication:
09 2020
Historique:
received: 10 03 2020
accepted: 27 05 2020
pubmed: 7 6 2020
medline: 25 5 2021
entrez: 7 6 2020
Statut: ppublish

Résumé

Transanal total mesorectal excision (taTME) is a novel approach to surgery for rectal cancer. The technique has gained significant popularity in the surgical community due to the promising ability to overcome technical difficulties related to the access of the distal pelvis. Recently, Norwegian surgeons issued a local moratorium related to potential issues with the safety of the procedure. Early adopters of taTME in Canada have recognized the need to create guidelines for its adoption and supervision. The objective of the statement is to provide expert opinion based on the best available evidence and authors' experience. The procedure has been performed in Canada since 2014 at different institutions. In 2016, the first Canadian taTME congress was held in the city of Toronto, organized by two of the authors. In early 2019, a multicentric collaborative was established [The Canadian taTME expert Collaboration] which aimed at ensuring safe performance and adoption of taTME in Canada. Recently surgeons from 8 major Canadian rectal cancer centers met in the city of Toronto on December 7 of 2019, to discuss and develop a position statement. There in person, meeting was followed by 4 rounds of Delphi methodology. The generated document focused on the need to ensure a unified approach among rectal cancer surgeons across the country considering its technical complexity and potential morbidity. The position statement addressed four domains: surgical setting, surgeons' requirements, patient selection, and quality assurance. Authors agree transanal total mesorectal excision is technically demanding and has a significant risk for morbidity. As of now, there is uncertainty for some of the outcomes. We consider it is possible to safely adopt this operation and obtain adequate results, however for this purpose it is necessary to meet specific requirements in different domains.

Identifiants

pubmed: 32504263
doi: 10.1007/s00464-020-07680-8
pii: 10.1007/s00464-020-07680-8
pmc: PMC7395021
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3748-3753

Références

Surg Endosc. 2016 Aug;30(8):3210-5
pubmed: 26537907
Br J Surg. 2010 Sep;97(9):1416-30
pubmed: 20632311
Dis Colon Rectum. 2017 Dec;60(12):1250-1259
pubmed: 29112560
Surg Endosc. 2018 Mar;32(3):1091-1103
pubmed: 29234940
Colorectal Dis. 2018 Jun;20(6):O143-O151
pubmed: 29693307
Updates Surg. 2019 Mar;71(1):13-15
pubmed: 30796631
Expert Rev Anticancer Ther. 2016 Nov;16(11):1145-1153
pubmed: 27690685
Surg Endosc. 2017 Jul;31(7):2711-2719
pubmed: 28462478
Surg Endosc. 2010 May;24(5):1205-10
pubmed: 20186432
Ann Surg. 2019 Sep 17;:
pubmed: 31567502
Dis Colon Rectum. 2017 Oct;60(10):1023-1031
pubmed: 28891845
Surg Endosc. 2020 Apr;34(4):1534-1542
pubmed: 29998391
Lancet. 2009 Mar 7;373(9666):821-8
pubmed: 19269520
Tech Coloproctol. 2019 Sep;23(9):803-806
pubmed: 31599386
Br J Surg. 2019 Aug;106(9):1120-1121
pubmed: 31304578
JAMA. 2000 Dec 20;284(23):3028-35
pubmed: 11122590
Tech Coloproctol. 2018 Apr;22(4):279-287
pubmed: 29569099
Tech Coloproctol. 2013 Jun;17(3):257-8
pubmed: 23519984
Ann Surg. 2016 Apr;263(4):745-50
pubmed: 25790120
J Am Coll Surg. 2008 Jun;206(6):1167-77
pubmed: 18501815
Cancer Manag Res. 2018 Nov 01;10:5239-5245
pubmed: 30464621
Surgery. 2016 Mar;159(3):736-48
pubmed: 26576696
Int J Surg Oncol. 2015;2015:464570
pubmed: 26425367
Tech Coloproctol. 2020 Apr;24(4):309-316
pubmed: 32112245
Colorectal Dis. 2018 Jan;20(1):O1-O6
pubmed: 29165862
Colorectal Dis. 2016 Jan;18(1):51-8
pubmed: 26603786
Tech Coloproctol. 2019 Sep;23(9):903-911
pubmed: 31599385
Surg Endosc. 2016 Feb;30(2):464-470
pubmed: 25921202
Postgrad Med J. 2007 Dec;83(986):777-9
pubmed: 18057179
Tech Coloproctol. 2019 Aug;23(8):703-705
pubmed: 31485771
BMC Cancer. 2017 Apr 11;17(1):253
pubmed: 28399840

Auteurs

Antonio Caycedo-Marulanda (A)

Kingston General Hospital, 76 Stuart Street, Kingston, ON, K7L 2V7, Canada. Antonio.Caycedo@kingstonhsc.ca.
Queen's University, Kingston, Canada. Antonio.Caycedo@kingstonhsc.ca.

Carl J Brown (CJ)

St. Paul's Hospital, Vancouver, Canada.
University of British Columbia, Vancouver, Canada.

Sami A Chadi (SA)

Toronto Western Hospital, Toronto, Canada.
University Health Network, Toronto, Canada.

Shady Ashamalla (S)

Sunnybrook Health Sciences Centre, Toronto, Canada.

Lawrence Lee (L)

McGill University Health Centre, Montreal, Canada.

Peter Stotland (P)

University Health Network, Toronto, Canada.
North York General Hospital, Toronto, Canada.

Usmaan Hameed (U)

University Health Network, Toronto, Canada.
North York General Hospital, Toronto, Canada.

George Melich (G)

University of British Columbia, Vancouver, Canada.
Royal Columbian Hospital/Eagle Ridge Hospital, New Westminster, Canada.

Grace Ma (G)

Health Sciences North, Sudbury, Canada.
Northern Ontario School of Medicine, Sudbury, Canada.

Francois Letarte (F)

CHU de Quebec, Québec, Canada.
Universite de Laval, Québec, Canada.

Ahmer Karimuddin (A)

St. Paul's Hospital, Vancouver, Canada.
University of British Columbia, Vancouver, Canada.

Fayez Quereshy (F)

Toronto Western Hospital, Toronto, Canada.
University Health Network, Toronto, Canada.

Terry Phang (T)

St. Paul's Hospital, Vancouver, Canada.
University of British Columbia, Vancouver, Canada.

Manoj Raval (M)

St. Paul's Hospital, Vancouver, Canada.
University of British Columbia, Vancouver, Canada.

Elena Vikis (E)

University of British Columbia, Vancouver, Canada.
Royal Columbian Hospital/Eagle Ridge Hospital, New Westminster, Canada.

A Sender Liberman (AS)

McGill University Health Centre, Montreal, Canada.

Alexandre Bouchard (A)

CHU de Quebec, Québec, Canada.
Universite de Laval, Québec, Canada.

Phillipe Bouchard (P)

CHU de Quebec, Québec, Canada.
Universite de Laval, Québec, Canada.

Sebastien Drolet (S)

CHU de Quebec, Québec, Canada.
Universite de Laval, Québec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH